Daiichi Starts Challenging Astellas For Japanese AML Market
October 10, 2019
Mutant Cells Team Up To Make An Even Deadlier Blood Cancer
October 03, 2019
Molecular Testing Becoming Essential in AML Treatment
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on whether the FLT3 test may be applied in newly diagnosed acute myelogenous leukemia (AML)
Published:12 December 2018
The published content on this page is not directed by any sponsors and is at the sole discretion of Caribou Publishing and the OBR editorial staff.
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.